Statin therapy was strongly associated with concomitant hypertension and cholesterol control (OR 10.7; 95% CI 8.1-14.3), which increased overall from 1.8% in 1988-1994 to 26.9% in 2005-2010.
Cross-Sectional
Despite significant improvements over time, control of concomitant hypertension and hypercholesterolemia remains suboptimal, particularly among older, minority, diabetic, and cardiovascular disease patients.
Absolute Event Rate: 26.9% vs 1.8%
BACKGROUND: Hypertension doubles coronary heart disease (CHD) risk. Treating hypertension only reduces CHD risk ≈25%. Treating hypercholesterolemia in hypertensive patients reduces residual CHD risk >35%. METHODS AND RESULTS: To assess progress in concurrent hypertension and hypercholesterolemia control, National Health and Nutrition Examination Surveys 1988 to 1994, 1999 to 2004, and 2005 to 2010 were analyzed. Hypertension was defined by blood pressure ≥140/≥90 mm Hg, current medication treatment, and 2-told hypertension status; blood pressure <140/<90 defined control. Hypercholesterolemia was defined by ATP III criteria based on 10-year CHD risk, low-density lipoprotein cholesterol (LDL-C), and non-high-density lipoprotein cholesterol; values below diagnostic thresholds defined control. Across surveys, 60.7% to 64.3% of hypertensives were hypercholesterolemic. From 1988 to 1994 to 2005 to 2010, control of LDL-C rose (9.2% 95% confidence interval (CI), 6.6%-11.9% to 45.4% 95% CI, 42.6%-48.3%), concomitant hypertension and LDL-C (5.0% 95% CI, 3.3%-6.7% to 30.7% 95% CI, 27.9%-33.4%), and combined hypertension, LDL-C, and non-high-density lipoprotein cholesterol (1.8% 95% CI, 0.4%-3.2% to 26.9% 95% CI, 24.4%-29.5%). By multivariable logistic regression, factors associated with concomitant hypertension, LDL-C, and non-high-density lipoprotein cholesterol control (odds ratio 95% CI) were statin (10.7 8.1-14.3) and antihypertensive (3.32 2.45-4.50) medications, age (0.77 0.69-0.88/10-year increase), ≥2 healthcare visits/yr (1.90 1.26-2.87), black race (0.59 0.44-0.80), Hispanic ethnicity (0.62 0.43-0.90), cardiovascular disease (0.44 0.34-0.56), and diabetes mellitus (0.54 0.42-0.70). CONCLUSIONS: Despite progress, opportunities for improving concomitant hypertension and hypercholesterolemia control persist. Prescribing antihypertensive and antihyperlipidemic medications to achieve treatment goals, especially for older, minority, diabetic, and cardiovascular disease patients, and accessing healthcare at least biannually could improve concurrent risk factor control and CHD prevention.
Egan et al. (2013) conducted a cross-sectional in Hypertension and hypercholesterolemia. Statin therapy was strongly associated with concomitant hypertension and cholesterol control (OR 10.7; 95% CI 8.1-14.3), which increased overall from 1.8% in 1988-1994 to 26.9% in 2005-2010.